Document Detail


Preserving target-organ function with candesartan cilexetil in patients with hypertension.
MedLine Citation:
PMID:  11059635     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Epidemiological evidence suggests that reducing blood pressure alone in hypertensive patients delays the onset of cardiovascular events without necessarily preventing the progression of chronic target-organ disease, such as end-stage renal failure and heart failure. Successful clinical management of hypertensive patients will therefore not be possible unless therapies are aimed both at the effective control of blood pressure and at the preservation of target-organ function. The new angiotensin II type I (AT1) receptor blocker candesartan cilexetil has been shown to be effective in reducing target-organ damage in animal models of hypertension, even at doses that do not produce significant reductions in blood pressure. Protective effects of candesartan cilexetil towards the heart and kidney have also been demonstrated in the clinical studies that have been conducted to date. Thus, candesartan cilexetil has been shown to induce regression of left ventricular hypertrophy within 8-12 weeks of treatment and to improve renal haemodynamics, both acutely and after 6 weeks of treatment in hypertensive patients. Furthermore, in hypertensive patients with co-existent non-insulin-dependent diabetes mellitus and microalbuminuria, 12 weeks of treatment with candesartan cilexetil, 8-16 mg, significantly reduced urinary albumin excretion. Clinical evidence is therefore accumulating that the antihypertensive efficacy and tolerability profile already established for candesartan cilexetil is combined with the renal and cardioprotective effects necessary for optimal management of hypertension.
Authors:
F Zannad
Related Documents :
11585015 - Diastolic dysfunction: insights into pathophysiology and pharmacotherapy.
6883905 - Effects of tiodazosin, a new antihypertensive, hemodynamics and clinical variables.
16763185 - Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of rando...
20529495 - How ready is general practice to improve quality in chronic kidney disease? a diagnosti...
24811635 - Homogenous nucleation rates of n-propanol measured in the laminar flow diffusion chambe...
1341225 - Serial changes of mitral flow pattern after percutaneous transvenous mitral commissurot...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Blood pressure. Supplement     Volume:  1     ISSN:  0803-8023     ISO Abbreviation:  Blood Press Suppl     Publication Date:  2000  
Date Detail:
Created Date:  2001-02-07     Completed Date:  2001-02-08     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  9300787     Medline TA:  Blood Press Suppl     Country:  NORWAY    
Other Details:
Languages:  eng     Pagination:  36-9     Citation Subset:  IM    
Affiliation:
Service de Cardiologie, Hôpital Central, Nancy, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin Receptor Antagonists*
Antihypertensive Agents / therapeutic use*
Benzimidazoles / therapeutic use*
Biphenyl Compounds / therapeutic use*
Humans
Hypertension / drug therapy*,  physiopathology
Hypertrophy, Left Ventricular / drug therapy
Kidney / drug effects,  physiopathology
Receptor, Angiotensin, Type 1
Receptor, Angiotensin, Type 2
Tetrazoles*
Chemical
Reg. No./Substance:
0/Angiotensin Receptor Antagonists; 0/Antihypertensive Agents; 0/Benzimidazoles; 0/Biphenyl Compounds; 0/Receptor, Angiotensin, Type 1; 0/Receptor, Angiotensin, Type 2; 0/Tetrazoles; R85M2X0D68/candesartan cilexetil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Improving prognosis in hypertension: exploring the benefits of angiotensin II type 1 receptor blocka...
Next Document:  Reducing cardiovascular morbidity and mortality in the elderly.